Peginterferon Lambda COVID-19 studies.
Submit updates/corrections .
Feb 1 |
(Preprint) (meta analysis) | Peginterferon Lambda for COVID-19: real-time meta analysis of 3 studies |
| Statistically significant improvement is seen for hospitalization. 2 studies from 2 independent teams in 2 different countries show statistically significant improvements in isolation (not for the most serious outcome). • Meta analysis .. | ||
Mar 17 |
(Preprint) | Eiger's Single-dose Peginterferon Lambda for COVID-19 Reduced Risk of Hospitalization or ER Visits by 50% in a Predominantly Vaccinated Population in Phase 3 TOGETHER Study |
| 72% lower mortality [p=0.38], 43% lower hospitalization [p=0.04], and 51% fewer combined hospitalization/ER visits [p=0.002]. High-risk outpatient RCT with 916 peginterferon lambda patients and 1,020 control patients, showing significantly lower hospitalization/ER visits with treatment. Single subcutaneous injection. For more discussion see [twitter.com]. | ||
Mar 30 2021 |
et al., Nature Communications, doi:10.1038/s41467-021-22177-1 | Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial |
| no change in hospitalization [p=1], 6% worse recovery [p=0.76], and 14% worse viral clearance [p=0.91]. RCT 120 outpatients with mild/moderate COVID-19, showing no significant differences with peginterferon lambda-1a treatment. 180μg subcutaneous peginterferon lambda-1a. NCT04331899. | ||
Nov 12 2020 |
et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(20)30566-X (date from earlier preprint) | Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial |
| 75% lower progression [p=0.35] and 66% improved viral clearance [p=0.03]. Small outpatient RCT with 30 peginterferon lambda and 30 control patients, showing improved viral clearance with treatment. Single subcutaneous injection of peginterferon lambda 180μg. NCT04354259. | ||
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.